Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Comparison of Beta-blockers and Calcium Channel Blockers in Atrial Fibrillation (BRACE-AFib)

12. november 2026 oppdatert av: University Hospital, Basel, Switzerland

BRACE-AFib: Beta-blocker Replacement and Calcium Channel Blockers Evaluation in Atrial Fibrillation

Beta-blockers are generally prescribed for the treatment of atrial fibrillation. Their purpose is to slow the heart rate and thereby reduce the workload on the heart. However, beta-blockers can affect patients' quality of life, for example by reducing physical performance or causing fatigue in daily life.

the aim of this study is to determine whether calcium channel blockers can improve the treatment of atrial fibrillation and have a positive impact on the quality of life of patients with atrial fibrillation compared with beta-blockers. It will also be investigated how calcium channel blockers affect the physical exercise capacity. In addition, potential side effects of both medications will be monitored and it will be explored whether there are any differences between women and men over the course of the study.

Both study medications, the calcium channel blocker diltiazem and the beta-blocker bisoprolol, are approved by authorities and are recommended by the European Society of Cardiology for rate control in atrial fibrillation.

Studieoversikt

Status

Har ikke rekruttert ennå

Detaljert beskrivelse

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia. Many AF patients present with a rapid ventricular response resulting in a high heart rate (HR). In these patients, it is important to lower the HR. To achieve rate control, several pharmacological agents are available, but beta-blockers (BB) are predominantly used. There is little evidence supporting the preference for BB. Side effects of BB such as fatigue, dizziness, and effort intolerance are widely known. Non-dihydropyridine calcium channel blockers (NDCC) represent an alternative for rate control and might be associated with better quality of life (QoL) than BB in AF patients. This study aims to investigate the impact on the QoL of AF patients who are currently on BB therapy and are switching to NDCC. Both men and women affected by AF and its complications will be enrolled in the study.

If this study can show an advantage of NDCC over BB in AF patients, a paradigm shift in the treatment of AF could take place. This could mean an easily implementable potential therapeutic advantage at no supplementary cost for patients and the health care system. Given the very common use of BB in AF patients, the negative impact of this drug on QoL could affect thousands of patients.

The investigational medicinal product (IMP) is diltiazem, a NDCC. Diltiazem belongs to the benzothiazepine class and exerts its pharmacological effect through inhibition of L-type calcium channels in atrioventricular nodal tissue, resulting in negative dromotropic effects and effective ventricular rate control in AF. Diltiazem is approved by the authorities and recommended by current guidelines as an alternative to BB for rate control in AF.

In the present study, diltiazem is administered orally in a prolonged-release formulation at daily doses of 90 mg, 180 mg, or 360 mg, corresponding to low, normal, or high dose categories. The comparator is bisoprolol, a β1-selective beta-adrenergic receptor blocker. BB are the most frequently prescribed agents for rate control in AF and represent the current standard of care. Bisoprolol is administered orally at daily doses of 2.5 mg, 5 mg, or 10 mg, reflecting standard clinical practice.

Patient representatives have been involved in developing our research from the beginning. Their insights have guided our approach to ensure the study addresses real concerns faced by patients affected by AF.

Studietype

Intervensjonell

Registrering (Antatt)

266

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Canton of Basel-City
      • Basel, Canton of Basel-City, Sveits, 4031
        • University Hospital Basel
        • Hovedetterforsker:
          • Patrick Badertscher, PD Dr. med.
        • Ta kontakt med:
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Documented AF
  • Currently on a stable regimen of BB for at least three weeks
  • Informed consent as documented by signature

Exclusion Criteria:

  • Left ventricular ejection fraction (LVEF) <40%
  • Severe valvular heart disease
  • Uncontrolled hypertension defined as systolic BP > 180 mmHg
  • AV block Type II, AV block type III
  • Severe bradycardia, defined as a resting heart rate <40 bpm on ECG
  • Currently on a NDCC (Diltiazem or Verapamil)
  • Concomitant rhythm-controlling medication (antiarrhythmic drugs Vaughan Williams classification I and III)
  • Currently on Ivabradine, Digoxin, Clonidine, Pimozide, Dihydroergotamine, Nifedipine, Lomitapide
  • History of atrio-ventricular node ablation
  • Implanted pacemaker or implantable cardioverter defibrillator (ICD) with a right-ventricular pacing burden >40%
  • Previous pulmonary vein isolation (PVI) or electric cardioversion within 90 days prior to study enrolment
  • Established infiltrative myocardial disease, e.g. amyloidosis, constrictive pericarditis, myocarditis, hypertrophic cardiomyopathy
  • End-stage renal disease, estimated glomerular filtration rate (eGFR) <15 ml/min/1.73 m2
  • Pregnant or breastfeeding women, or women of childbearing potential who do not use a highly effective form of birth control
  • Expected life expectancy < 6months
  • Drug or alcohol abuse
  • Inability to understand and sign study information and patient informed consent

Both women and men will be enrolled, and sex-specific differences in treatment effects will be examined in a subgroup analysis. No vulnerable populations will be included. All participants are capable of judgment.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Diltiazem

133 patients are randomized to the experimental intervention and treated with the non-dihydropyridine calcium channel blocker (NDCC) Diltiazem.

Study participants randomized in the experimental intervention group will receive Non-dihydropyridine calcium channel blockers (NDCC) Diltiazem retard for 90 days. Depending on the dosage of the beta-blocker treatment of these patients at baseline, three different dosage options will be used (low, normal, high). Diltiazem capsules of 90mg will be provided, meaning that patients with the low dosage will take one capsule a day (morning), patients with the normal dosage two capsules a day (morning and evening) and patients with the high dosage four capsules a day (2x morning and 2x evening). Based on previous data, we assume that most patients will use the low or normal dosage. The medication Diltiazem 90mg will be over-encapsulated, packed and labelled by a pharmacy specialist.

Aktiv komparator: Bisoprolol

133 patients are randomized to the control arm and treated with the beta-blocker Bisoprolol.

Study patients will receive the beta-blocker (BB) Bisoprolol for 90 days. Depending on the dosage of the BB treatment of these patients at baseline, three different dosage options will be used (low, normal high). Low dosage of Bisoprolol is corresponding to 2.5mg, normal dosage to 5mg and high dosage to 10mg/day. Bisoprolol capsules of 2.5mg will be provided, meaning that patients with the low dosage will take one capsule a day (morning), patients with the normal dosage two capsules a day (morning and evening) and patients with the high dosage four capsules (2x morning and 2x evening). The medication Bisoprolol will be over-encapsulated, packed and labelled by a pharmacy specialist.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Atrial-Fibrillation-related Quality of Life
Tidsramme: From baseline to 3 months

Change in Atrial-Fibrillation-related Quality of Life between Non-dihydropyridine calcium channel blockers (NDCC) versus continuation of beta-blockers (BB) from baseline to 3 months in patients with Atrial-Fibrillation.

The primary outcome uses the AFEQT questionnaire:

The AFEQT 20-item questionnaire is a validated, AF-specific QoL tool. It assesses 4 domains: symptoms, daily activities, treatment concerns, and treatment satisfaction. The overall AFEQT score is calculated using the first 3 domains and ranges from 0 = worst to 100 = best QoL. Additionally, for each domain of interest, there is a corresponding subscale score: symptoms, daily activities, treatment concerns, and treatment satisfaction subscale scores. Each subscale ranges from 0 = worst to 100 = best QoL and is scored separately. The AFEQT questionnaire will be done at baseline before the intake of the first study drug and after three months of intervention.

From baseline to 3 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
NT-proBNP
Tidsramme: At Baseline and 3 months

Change in NT-proBNP levels measured at baseline and after 3 months.

NT-proBNP is released into the circulation in response to myocardial cell stretch. This biomarker is commonly used to evaluate the degree of heart failure in cardiac patients. Non-fasting blood samples will be taken at baseline before randomization and at the final study visit (4.7ml each). NT-proBNP levels will be measured in the laboratory of the respective study site by using an electrochemiluminescence immunoassay (Elecsys, Roche Diagnostics, Switzerland). Furthermore, if patients provide consent, additional blood samples (serum, plasma and whole blood) will be taken, processed, frozen and stored at -80°C, according to the ethical guidelines concerning biobanking, at the Cardiovascular Research Institute Basel. These samples will be used for future genetic analyses and for the assessment of emerging biomarkers of interest in this context.

At Baseline and 3 months
6-minute walking test (6MWT) distance
Tidsramme: At baseline and 3 months

Change in 6MWT distance assessed at baseline and after 3 months

The 6MWT is a simple test which does not require expensive equipment or advanced training for technicians. The test involves asking the patient to walk the longest distance possible in a set interval of 6 minutes, through a walking course (corridor) preferably 30 meters long. The result of the 6MWT will be entered in the CRF as the distance in meters. In this context, other variables will be assessed, including the Borg Scale after the test and information on whether the test was done with a walking aid or must be terminated earlier. The 6MWT will be done at baseline before randomization and after 3 months of intervention.

At baseline and 3 months
Peak flow measurement
Tidsramme: At baseline and 3 months

Change in peak flow measured at baseline and at the study end visit after 90 days of study intervention. The patient will perform the test in a standing position. Study personnel will instruct the patient to inhale as deeply as possible and then exhale as forcefully and rapidly as they can. The measurement will be repeated three times, and the results of all three attempts will be recorded in the study database.

At baseline and 3 months
Hierarchical composite endpoint comprising
Tidsramme: Baseline to 3 months

A hierarchical win ratio will be calculated comparing participants between treatment groups using the following pre-specified hierarchy (in order of priority), all assessed as change from baseline to 3 months:

  • AF-related QoL
  • 6MWT distance
  • NT-proBNP
Baseline to 3 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Patrick Badertscher, PD Dr. med., University Hospital, Basel, Switzerland

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

1. oktober 2029

Studiet fullført (Antatt)

1. oktober 2029

Datoer for studieregistrering

Først innsendt

22. oktober 2026

Først innsendt som oppfylte QC-kriteriene

22. oktober 2026

Først lagt ut (Faktiske)

29. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere